ArticleAmerican journal of cancer research2025
Transcriptomic validation and clinical translation of CCDC78 as a prognostic biomarker in colorectal cancer.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- CCDC78 is required for prostate cancer cell growth and serves as a prognostic biomarker for high-risk disease.Discover oncology · 2026Article
- Integrated bioinformatics and experimental validation identify CCDC78 as a prognostic biomarker in colon adenocarcinoma.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates CCDC78 as a potential prognostic biomarker in colorectal cancer (CRC), incorporating both clinical correlation and functional validation. Analysis of 135 paired tumor and adjacent tissues revealed significantly elevated CCDC78 expression in tumor tissues (P<0.001), and higher expression levels were associated with markedly lower 5-year survival rates (P=0.001). Time-dependent ROC curves demonstrated robust prognostic performance at 12, 36, and 60 months (AUCs of 0.85, 0.84, and 0.82, respectively). In vitro assays showed that CCDC78 overexpression significantly enhanced cell proliferation, migration, and invasion (P<0.05), whereas siRNA-mediated knockdown suppressed these phenotypes and increased apoptosis (P<0.01). Cox regression analyses identified CCDC78 as an independent prognostic factor (P=0.02). Notably, despite similar baseline expression across CRC cell lines, SW480 cells were more sensitive to knockdown, while HCT116 cells more strongly recapitulated the overexpression phenotype. TCGA pan-cancer analysis showed upregulated CCDC78 in various tumors, including CRC, adrenocortical carcinoma (ACC), bladder cancer (BLCA), and kidney renal clear cell carcinoma (KIRC), reinforcing its broad oncogenic relevance. Correlation analyses linked high CCDC78 expression to older age, poor tumor differentiation, advanced TNM stage, lymph node metastasis, and distant metastasis. Immune profiling revealed negative associations with 11 immune cell types but a positive correlation with NK CD56 bright cells. Gene set enrichment analysis (GSEA) implicated CCDC78 in interferon-JAK-STAT, RIG-I/NFκB, and WNT signaling pathways. Altogether, these findings suggest that CCDC78 promotes CRC progression through enhancing tumor cell aggressiveness and modulating the immune microenvironment, underscoring its potential as a prognostic biomarker and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.